Menu
  • Home
  • London Exchange
  • Euronext
  • Australian Exchange
  • Wire
  • Contact Us
  • Business & Finance
NewsnReleases

EBR appoints Erik Strandberg as Chief Commercial Officer

Posted on April 18, 2024April 18, 2024

SYDNEY: EBR Systems, Inc. (ASX: “EBR”), developer of the world’s only wireless cardiac pacing device for heart failure, announced the appointment of Mr. Erik Strandberg as Chief Commercial Officer (“CCO”) of the Company, effective as of 29 April 2024.

Mr. Strandberg will lead the Company’s US commercialization strategy and will immediately focus on preparing the Company for product launch and commercialization in early 2025.

Mr. Strandberg has over two decades of medical device industry sales experience and has developed relationships across a broad spectrum of physicians, C-suite hospital executives, and medical professionals.

He has demonstrated exceptional strategic sales planning, contract negotiation, operational oversight, and leadership expertise.

Prior to joining EBR, Mr. Strandberg was the Senior Vice President of the Hybrid Therapies Division at AtriCure (NASDAQ:ATRC), where he led the promotion and sales initiatives for a prestigious product portfolio targeting the treatment of Atrial Fibrillation and related conditions.

Before that, Mr. Strandberg was at Boston Scientific (NYSE:BSX) where he helped execute the commercial launch strategy of the Watchman Left Atrial Appendage Closure device. He previously held leadership roles at St Jude Medical and Guidant Corporation.

Mr. Strandberg holds a Bachelor of Science in Finance from Florida State University and has completed Executive Education Programs at the University of Texas McCombs School of Business and the Wharton School of Business at the University of Pennsylvania.

Mr. Strandberg is also a Certified Healthcare Financial Professional and has specialized knowledge in Cardiac Pacing & Implantable Cardioverter Defibrillators from the Arrhythmia Technologies Institute.

John McCutcheon, EBR Systems’ President & Chief Executive Officer, said: “We’re excited to have someone of Erik’s vast experience and caliber leading EBR’s commercial strategies as we approach final regulatory approval and seek to commercialize in early 2025. Erik’s track record in successfully driving growth within the medical device sales industry is welcomed and his strategic insight to lead high-performing teams makes him perfectly suited to take on this role.”

Erik Strandberg, EBR Systems’ Chief Commercial Officer, said: “I am thrilled to be joining the EBR team and leading what is a significant unmet market opportunity. With the innovative WiSE product and the committed team we have, I look forward to leveraging my commercial experience and relationships in the industry to drive new opportunities and deliver growth to shareholders.”

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Track all markets on TradingView

Investing.com .

Site Navigation

  • Home
  • Listed Companies
  • Contact Us
  • London Stock Exchange
  • Singapore Exchange
  • Canadian Exchange
  • Australian Exchange
  • Oslo Bourse
  • PSX
  • Ratings
  • Euronext
  • MENA
  • Nasdaq Nordic
  • Wire
  • Business & Finance
  • Gadget Reviews
  • About Us: A Comprehensive Financial News Database

All news and articles on NewsnReleases are based on press releases, corporate announcements and analysts’ reports issued to London Stock Exchange (LSE), Euronext, Singapore Exchange (SGX), Japan Stock Exchange (JPX), Dubai Financial Market (DFM), Saudi Stock Exchange (Tadawul), Qatar Stock Exchange (QSE), BSEIndia, Australia Stock Exchange etc.

Listed Companies

Equity Markets and Stock Exchanges

NNR

©2025 NewsnReleases | WordPress Theme by Superb WordPress Themes